July 26, 2024 – Page 4 – Goldea Capital

MISTRAS Group Announces Conference Call to Discuss Second Quarter Results on August 1, 2024

Written by Customer Service on July 26, 2024. Posted in Public Companies.

PRINCETON JUNCTION, N.J., July 26, 2024 (GLOBE NEWSWIRE) — MISTRAS Group, Inc. (MG: NYSE) has scheduled a conference call for Thursday, August 1, 2024 at 9:00 am Eastern Time to discuss its results for the second quarter of 2024. A press release with the second quarter results will be issued after the close of market on Wednesday, July 31, 2024. To listen to the live webcast of the conference call, visit the Investor Relations section of MISTRAS Group’s website at www.mistrasgroup.com. Individuals wishing to participate in the live question and answer session may pre-register at: https://register.vevent.com/register/BI05aef0d9604542e897138e5abb38ad5a. Following the conference call, an archived webcast of the call will be available for one year by visiting the Investor Relations section of MISTRAS Group’s website. About MISTRAS...

Bank of the James Announces Second Quarter, First Half of 2024 Financial Results and Declaration of Dividend

Written by Customer Service on July 26, 2024. Posted in Public Companies.

Deposit Expansion, Market Share Growth, Asset Quality LYNCHBURG, Va., July 26, 2024 (GLOBE NEWSWIRE) — Bank of the James Financial Group, Inc. (the “Company”) (NASDAQ:BOTJ), the parent company of Bank of the James (the “Bank”), a full-service commercial and retail bank, and Pettyjohn, Wood & White, Inc. (“PWW”), an SEC-registered investment advisor, today announced unaudited results of operations for the three month and six month periods ended June 30, 2024. The Bank serves Region 2000 (the greater Lynchburg MSA) and the Blacksburg, Buchanan, Charlottesville, Harrisonburg, Lexington, Nellysford, Roanoke, and Wytheville, Virginia markets. Net income for the three months ended June 30, 2024 was $2.15 million or $0.47 per basic and diluted share compared with $2.53 million or $0.56 per basic and diluted share for the three months...

CNOVA NV 2024 Second Quarter Activity & First Half Financial Performance

Written by Customer Service on July 26, 2024. Posted in Earnings Releases And Operating Results.

CNOVA N.V.First Half Financial performance & Second Quarter 2024 activityUpdate on Casino group situation Cnova pursues its path towards operational profitability with an improving EBITDA after rents by +€2m and free cash-flows improving by +€101m vs. 23 Product GMV1 gradually improving month after month: Marketplace: -5% in 1Q24, -4% in April, -1% in May, +2% in June and +7% in July2 Direct sales: -28% in 1Q24, -26% in April, -28% in May, -18% in June and -9% in July2 Product GMV1 declining by -12% in 1H24 vs. 23, improving compared to FY23 trend Like-for-like3 Overall GMV declining by -11% in 1H24 vs. 23, improving compared to FY23 trend (-14% vs. 22). With the successful implementation of the transformation plan, Cnova is now gradually recovering in 2Q24 (-9% vs. 23) compared to 1Q24 (-12% vs. 23) in a challenging...

Maisons du Monde : Q2 sales and First Half results 2024

Written by Customer Service on July 26, 2024. Posted in Earnings Releases And Operating Results.

PRESS RELEASENantes, le 26 July 2024 Q2 sales and First Half results 2024 Inspire Everyday plan on track Q2 activity impacted in June by macroeconomic uncertainties Gross margin rises 150 bps, reaching 65.3% Free Cash Flow nearly stable compared to H1 2023 Gross margin up 150 bps to 65.3%, partially balancing a -9.6% drop in sales Free Cash Flow nearly stable as expected, with cost & cash initiatives offsetting a negative EBIT Adaptation of the store network is accelerating: 5 store openings in H1, including 2 under affiliation Renewed concept successfully tested on 3 pilot stores with double-digit higher performance compared to the network, rolled out to 17 stores with limited investment, in line with our agenda to revamp 70 stores in 2024 Positive results from 5 affiliate stores in operation for one year, confirming 2024 target...

Roadzen Secures Mizuho Debt Extension and Facility Increase

Written by Customer Service on July 26, 2024. Posted in Public Companies.

Additional $4 Million and Extension of Maturity on Existing $7.5 Million Facility NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) — Roadzen Inc. (Nasdaq: RDZN) (“Roadzen” or the “Company”), a global leader in AI at the convergence of insurance and mobility, today announced that it secured an extension of the maturity date and an additional $4.0 million of capital from Mizuho Securities USA LLC, a leading global investment bank and securities firm. The amended facility increases the loan from $7.5 million to $11.5 million of 15% senior secured notes, without any additional warrants, and extends the maturity date to December 31, 2024. “We greatly appreciate Mizuho’s continued belief in our vision. This extension and facility increase, combined with management’s recent debt-to-equity exchange, advances our continuing...

Sunstone IV hf. announces change of name to Míla Holding hf.

Written by Customer Service on July 26, 2024. Posted in Public Companies.

Sunstone IV hf. announces change of name to Míla Holding hf. Shareholders’ of Sunstone IV hf., reg. no. 620921-2540 (the “Company”) approved on 20 June 2024 to change the Company’s name from Sunstone IV hf. to Míla Holding hf. The name change was registered in the Icelandic Company Registry (Icel. Fyrirtækjaskrá) on 24 July 2024. The identities of the Company’s issued securities did not change. For more information please contact: Inga Helga HalldórudóttirCompliance officerMíla Holding hf. ingah@mila.is Attachment 20240625_GNW – Name Change -FINAL-

BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo

Written by Customer Service on July 26, 2024. Posted in Public Companies.

July 26, 2024 News Release BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo ADLM 2024 Conference – Chicago, July 26, 2024 – BioPorto Diagnostics, a company specializing in in vitro diagnostics with an emphasis on the early detection of Acute Kidney Injury (AKI), will be participating in the Association for Diagnostics and Laboratory Medicine (ADLM) 2024 clinical lab expo. BioPorto will feature its FDA-cleared product designed for pediatric AKI risk assessment, ProNephro AKI™ (NGAL), at this conference. ProNephro AKI is based on the NGAL (neutrophil gelatinase-associated lipocalin) biomarker and is the first FDA-cleared assay of its kind for the pediatric population. The authorization by FDA provides healthcare professionals with an additional tool for evaluating the risk of AKI. ADLM 2024 (formerly...

Beyond Ordinary Events, Inc.’s POSSIBLE, Announces Acquisition by Leading Events Organizer Hyve Group

Written by Customer Service on July 26, 2024. Posted in Mergers And Acquisitions.

Acquisition Positions POSSIBLE for Future Growth & Supports Expansion Goals NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) — Beyond Ordinary Events, Inc. (BOE)’s POSSIBLE, the premier marketing tentpole announced today that it has been acquired by Hyve Group, one of the world’s leading organizers of next-generation events. By joining forces, Hyve and POSSIBLE will combine resources to deliver a unique platform and experience that continues to bring marketers, business leaders and visionaries across the marketing, media, and technology industry together to be inspired, to drive progress and deliver solutions around their most challenging marketplace issues. Christian Muche, Co-Founder and CEO of Beyond Ordinary Events, will serve as Global President. Muche will continue to focus and lead on POSSIBLE’s future growth and deliver...

VALUE LINE, INC. ANNOUNCES HIGHER FISCAL YEAR 2024 EARNINGS

Written by Customer Service on July 26, 2024. Posted in Public Companies.

New York, July 26, 2024 (GLOBE NEWSWIRE) — Value Line, Inc., (NASDAQ: VALU) reported results for the fiscal year ended April 30, 2024. During the twelve months ended April 30, 2024, the Company’s net income of $19,016,000, or $2.02 per share, was 5.2% above net income of $18,069,000, or $1.91 per share, for the twelve months ended April 30, 2023. The Company’s receipts of $13,282,000 from its non-voting revenues interest in EAM and non-voting profits interest in EAM increased $2,151,000 or 19.3% above the prior fiscal year. For the twelve months ended April 30, 2024, excluding restructuring costs related to outsourcing to two U.S. based companies of certain fulfillment and distribution operations, operating expenses decreased approximately 1.0% below those during the twelve months ended April 30, 2023. During the three months ended...

Junshi Biosciences Announces Positive Opinion from the European Medicines Agency’s CHMP For Toripalimab

Written by Customer Service on July 26, 2024. Posted in Public Companies.

SHANGHAI, July 26, 2024 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, and its wholly-owned subsidiary TopAlliance Biosciences Inc. (TopAlliance Biosciences), announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion for the marketing authorization application (MAA) for toripalimab (European trade name: LOQTORZI®). The CHMP recommends approval for toripalimab for two indications: Toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal...

Day: July 26, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice